RecruitingPHASE1, PHASE2NCT07463599
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Studying Rare genetic tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HonorHealth Research Institute
- Intervention
- Tegavivint(drug)
- Enrollment
- 126 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
Collaborators
Iterion Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07463599 on ClinicalTrials.gov